7/17/22, 2:49 PM
`
`Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
`
`Nielsen's BASES Names LUMIFY® Eye
`Drops To 2020 U.S. BASES Top 25
`Breakthrough Innovations List
`
`NEWS PROVIDED BY
`Bausch Health Companies Inc.
`
`Oct 01, 2020, 07:00 ET
`
`Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)
`
`(PRNewsfoto/Bausch Health Companies)
`
`
`
`
`
`
`
`https://www.prnewswire.com/news-releases/nielsens-bases-names-lumify-eye-drops-to-2020-us-bases-top-25-breakthrough-innovations-list-30114376… 1/5
`
`Eye Therapies Exhibit 2125, 1 of 5
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/17/22, 2:49 PM
`Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
`LUMIFY® Recognized in the "Superstar" Category for Exceptional Sales and Growth
`
`LAVAL, QC, Oct. 1, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of
`Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that
`BASES, a Nielsen Global Consumer business division, has named LUMIFY® (brimonidine
`tartrate ophthalmic solution 0.025%) redness reliever eye drops to its 2020 U.S. BASES Top 25
`Breakthrough Innovations List in the "Superstar" category for its success in driving sales and
`category growth. The Top 25 Breakthrough Innovations List has been the gold standard for
`nearly a decade in recognizing innovation and global success within the Consumer Packaged
`Goods (CPG) space.
`
`"We're proud LUMIFY has been recognized by Nielsen's BASES on its 2020 U.S. BASES Top 25
`Breakthrough Innovations List," said Joe Gordon, U.S. president, Bausch + Lomb. "This
`prestigious recognition is a testament to the positive consumer response we have continued to
`receive on LUMIFY, which has helped drive growth to the once at redness reliever category. We
`remain steadfast in our commitment to bringing products like LUMIFY to market to meet the
`ever-evolving needs of consumers."
`
`Since Bausch + Lomb rst launched LUMIFY in 2018, these one of a kind OTC eye drops that
`contain low-dose brimonidine have become ingrained in popular culture through an ongoing
`surround-sound integrated consumer campaign highlighting their ability to signicantly
`reduce redness to help eyes appear whiter, brighter and more radiant for up to eight hours
`when used as directed. As a result, LUMIFY has achieved the No. 1 dollar share among redness
`relievers (at 40% share in the latest 52 weeks) , became the No. 1 eye doctor recommended
`1
`brand within the rst few months of launch, and brought in more than a million rst-time
`2
`users into the eye redness reliever category.
`3
`
`"Our Superstar category celebrates the best of what marketers do to drive growth, and we
`selected LUMIFY based on its strong business performance in years one and two, and the
`success it had in growing a category through premiumization," said Ben Macedo, BASES
`
`https://www.prnewswire.com/news-releases/nielsens-bases-names-lumify-eye-drops-to-2020-us-bases-top-25-breakthrough-innovations-list-30114376… 2/5
`
`
`
`Eye Therapies Exhibit 2125, 2 of 5
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/17/22, 2:49 PM
`Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
`Leader, North America. "Bausch + Lomb successfully married a novel formulation with a fresh
`national marketing campaign that caught re in the popular culture and on social media,
`spurring LUMIFY to capture the hearts of consumers."  
`
`LUMIFY was also recently recognized in IRI's 2019 New Product Pacesetters™ 25th annual re-
`port, which highlights the most successful new product launches across food and beverage,
`non-food and convenience store sectors. LUMIFY was named alongside nine other products in
`the non-food category for their ability to retain their unique, targeted appeal as niche products
`within mass-market outlets.
`
`For more information on LUMIFY, visit www.lumifydrops.com. To view the full U.S. BASES Top 25
`Breakthrough Innovations List, click here.
`
`About LUMIFY® Redness Reliever Eye Drops
`LUMIFY is the rst and only over-the-counter eye drops developed with low dose brimonidine
`tartrate 0.025% for the relief of redness of the eye due to minor irritations. Unlike other redness
`relievers, LUMIFY selectively targets redness, with a reduced risk of certain side effects,
`including rebound redness and loss of efcacy over time, when used as directed. LUMIFY is also
`the No. 1 eye doctor recommended redness reliever brand with approximately 79 percent of
`doctor recommendations.  For more information on LUMIFY, visit www.lumifydrops.com.
`2
`
`About Bausch + Lomb
`Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely
`focused on helping people see better. Its core businesses include over-the-counter products,
`dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care
`products, ophthalmic surgical devices and instruments. Bausch + Lomb develops,
`manufactures and markets one of the most comprehensive product portfolios in the industry,
`which is available in approximately 100 countries. For more information, visit
`www.bausch.com.  
`
`https://www.prnewswire.com/news-releases/nielsens-bases-names-lumify-eye-drops-to-2020-us-bases-top-25-breakthrough-innovations-list-30114376… 3/5
`
`
`
`Eye Therapies Exhibit 2125, 3 of 5
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
`
`7/17/22, 2:49 PM
`About Bausch Health
`Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to
`improve people's lives with our health care products. We develop, manufacture and market a
`range of pharmaceutical, medical device and over-the-counter products, primarily in the
`therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our
`commitments as we build an innovative company dedicated to advancing global health. More
`information can be found at www.bauschhealth.com.
`
`Forward-looking Statements
`This news release may contain forward-looking statements, which may generally be identied
`by the use of the words
`"anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates,"
`"potential," "target," or "continue" and variations or similar expressions. These statements are
`based upon the current expectations and beliefs of management and are subject to certain
`risks and uncertainties that could cause actual results to differ materially from those described
`in the forward-looking statements. These risks and uncertainties include, but are not limited to,
`the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-
`K and detailed from time to time in Bausch Health's other lings with the U.S. Securities and
`Exchange Commission and the Canadian Securities Administrators, which factors are
`incorporated herein by reference. They also include, but are not limited to, risks and
`uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that
`pandemic and its potential effects, the severity, duration and future impact of which are highly
`uncertain and cannot be predicted, and which may have a material adverse impact on Bausch
`Health, including but not limited to its project development timelines, and costs (which may
`increase). Readers are cautioned not to place undue reliance on any of these forward-looking
`statements. These forward-looking statements speak only as of the date hereof. Bausch Health
`undertakes no obligation to update any of these forward-looking statements to reect events
`or circumstances after the date of this news release or to reect actual outcomes, unless
`required by law.
`
`References:
`
`https://www.prnewswire.com/news-releases/nielsens-bases-names-lumify-eye-drops-to-2020-us-bases-top-25-breakthrough-innovations-list-30114376… 4/5
`
`
`
`Eye Therapies Exhibit 2125, 4 of 5
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/17/22, 2:49 PM
`Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
`1. Consumer Data Science: EDGE, Amazon, COSTCO Database, IRI, Total US MULO Data
`Ending 09-20-20.
`2. Consumer Data Science: EDGE, Amazon, + IRI, Total US MULO Data Ending 09-06-20.
`3. Consumer Data Science: IRI, Total US All Outlet Panel Data Ending 09-06-20.
`
`LUMIFY is a trademark of Bausch & Lomb Incorporated or its afliates. Any other
`product/brand names are trademarks of the respective owners. © 2020 Bausch & Lomb
`Incorporated or its afliates.
`LUM.0342.USA.20
`
`Investor Contact:
`Arthur Shannon
`arthur.shannon@bauschhealth.com
`(514) 856-3855
`(877) 281-6642 (toll free)
`
`Media Contact:
`Lainie Keller
`lainie.keller@bauschhealth.com
`(908) 927-1198
`
`SOURCE Bausch Health Companies Inc.
`
`Related Links
`http://www.bauschhealth.com
`
`https://www.prnewswire.com/news-releases/nielsens-bases-names-lumify-eye-drops-to-2020-us-bases-top-25-breakthrough-innovations-list-30114376… 5/5
`
`
`
`Eye Therapies Exhibit 2125, 5 of 5
`Slayback v. Eye Therapies - IPR2022-00142
`
`